These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 21543343)

  • 1. A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis.
    Burn J; Bishop DT; Chapman PD; Elliott F; Bertario L; Dunlop MG; Eccles D; Ellis A; Evans DG; Fodde R; Maher ER; Möslein G; Vasen HF; Coaker J; Phillips RK; Bülow S; Mathers JC;
    Cancer Prev Res (Phila); 2011 May; 4(5):655-65. PubMed ID: 21543343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetics, inheritance and strategies for prevention in populations at high risk of colorectal cancer (CRC).
    Burn J; Mathers J; Bishop DT
    Recent Results Cancer Res; 2013; 191():157-83. PubMed ID: 22893205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemoprevention with low-dose aspirin, mesalazine, or both in patients with familial adenomatous polyposis without previous colectomy (J-FAPP Study IV): a multicentre, double-blind, randomised, two-by-two factorial design trial.
    Ishikawa H; Mutoh M; Sato Y; Doyama H; Tajika M; Tanaka S; Horimatsu T; Takeuchi Y; Kashida H; Tashiro J; Ezoe Y; Nakajima T; Ikematsu H; Hori S; Suzuki S; Otani T; Takayama T; Ohda Y; Mure K; Wakabayashi K; Sakai T
    Lancet Gastroenterol Hepatol; 2021 Jun; 6(6):474-481. PubMed ID: 33812492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemoprevention of colorectal cancer: systematic review and economic evaluation.
    Cooper K; Squires H; Carroll C; Papaioannou D; Booth A; Logan RF; Maguire C; Hind D; Tappenden P
    Health Technol Assess; 2010 Jun; 14(32):1-206. PubMed ID: 20594533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.
    Burke CA; Dekker E; Samadder NJ; Stoffel E; Cohen A
    BMC Gastroenterol; 2016 Aug; 16(1):87. PubMed ID: 27480131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The protocol for a European double-blind trial of aspirin and resistant starch in familial adenomatous polyposis: the CAPP study. Concerted Action Polyposis Prevention.
    Burn J; Chapman PD; Mathers J; Bertario L; Bishop DT; Bülow S; Cummings J; Phillips R; Vasen H
    Eur J Cancer; 1995; 31A(7-8):1385-6. PubMed ID: 7577057
    [No Abstract]   [Full Text] [Related]  

  • 7. A randomized controlled trial of eicosapentaenoic acid and/or aspirin for colorectal adenoma prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme (The seAFOod Polyp Prevention Trial): study protocol for a randomized controlled trial.
    Hull MA; Sandell AC; Montgomery AA; Logan RF; Clifford GM; Rees CJ; Loadman PM; Whitham D
    Trials; 2013 Jul; 14():237. PubMed ID: 23895505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preventive effects of low-dose aspirin on colorectal adenoma growth in patients with familial adenomatous polyposis: double-blind, randomized clinical trial.
    Ishikawa H; Wakabayashi K; Suzuki S; Mutoh M; Hirata K; Nakamura T; Takeyama I; Kawano A; Gondo N; Abe T; Tokudome S; Goto C; Matsuura N; Sakai T
    Cancer Med; 2013 Feb; 2(1):50-6. PubMed ID: 24133627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemoprevention in Lynch syndrome.
    Burn J; Mathers JC; Bishop DT
    Fam Cancer; 2013 Dec; 12(4):707-18. PubMed ID: 23880960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can resistant starch and/or aspirin prevent the development of colonic neoplasia? The Concerted Action Polyp Prevention (CAPP) 1 Study.
    Mathers JC; Mickleburgh I; Chapman PC; Bishop DT; Burn J;
    Proc Nutr Soc; 2003 Feb; 62(1):51-7. PubMed ID: 12740057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients.
    Sinicrope FA; Half E; Morris JS; Lynch PM; Morrow JD; Levin B; Hawk ET; Cohen DS; Ayers GD; Stephens LC;
    Cancer Epidemiol Biomarkers Prev; 2004 Jun; 13(6):920-7. PubMed ID: 15184247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary chemoprevention of familial adenomatous polyposis with sulindac.
    Giardiello FM; Yang VW; Hylind LM; Krush AJ; Petersen GM; Trimbath JD; Piantadosi S; Garrett E; Geiman DE; Hubbard W; Offerhaus GJ; Hamilton SR
    N Engl J Med; 2002 Apr; 346(14):1054-9. PubMed ID: 11932472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aspirin and familial adenomatous polyposis: coming full circle.
    Chan AT
    Cancer Prev Res (Phila); 2011 May; 4(5):623-7. PubMed ID: 21543340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial.
    Burn J; Gerdes AM; Macrae F; Mecklin JP; Moeslein G; Olschwang S; Eccles D; Evans DG; Maher ER; Bertario L; Bisgaard ML; Dunlop MG; Ho JW; Hodgson SV; Lindblom A; Lubinski J; Morrison PJ; Murday V; Ramesar R; Side L; Scott RJ; Thomas HJ; Vasen HF; Barker G; Crawford G; Elliott F; Movahedi M; Pylvanainen K; Wijnen JT; Fodde R; Lynch HT; Mathers JC; Bishop DT;
    Lancet; 2011 Dec; 378(9809):2081-7. PubMed ID: 22036019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non steroidal anti-inflammatory drugs (NSAID) and Aspirin for preventing colorectal adenomas and carcinomas.
    Asano TK; McLeod RS
    Cochrane Database Syst Rev; 2004; 2004(2):CD004079. PubMed ID: 15106236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Sulindac and Erlotinib vs Placebo With Colorectal Neoplasia in Familial Adenomatous Polyposis: Secondary Analysis of a Randomized Clinical Trial.
    Samadder NJ; Kuwada SK; Boucher KM; Byrne K; Kanth P; Samowitz W; Jones D; Tavtigian SV; Westover M; Berry T; Jasperson K; Pappas L; Smith L; Sample D; Burt RW; Neklason DW
    JAMA Oncol; 2018 May; 4(5):671-677. PubMed ID: 29423501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eicosapentaenoic acid reduces rectal polyp number and size in familial adenomatous polyposis.
    West NJ; Clark SK; Phillips RK; Hutchinson JM; Leicester RJ; Belluzzi A; Hull MA
    Gut; 2010 Jul; 59(7):918-25. PubMed ID: 20348368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intestinal tumorigenesis in the Apc1638N mouse treated with aspirin and resistant starch for up to 5 months.
    Williamson SL; Kartheuser A; Coaker J; Kooshkghazi MD; Fodde R; Burn J; Mathers JC
    Carcinogenesis; 1999 May; 20(5):805-10. PubMed ID: 10334197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rectal epithelial apoptosis in familial adenomatous polyposis patients treated with sulindac.
    Keller JJ; Offerhaus GJ; Polak M; Goodman SN; Zahurak ML; Hylind LM; Hamilton SR; Giardiello FM
    Gut; 1999 Dec; 45(6):822-8. PubMed ID: 10562579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ursodeoxycholic acid counteracts celecoxib in reduction of duodenal polyps in patients with familial adenomatous polyposis: a multicentre, randomized controlled trial.
    van Heumen BW; Roelofs HM; Vink-Börger ME; Dekker E; Mathus-Vliegen EM; Dees J; Koornstra JJ; Langers AM; Nagtegaal ID; Kampman E; Peters WH; Nagengast FM
    Orphanet J Rare Dis; 2013 Aug; 8():118. PubMed ID: 23919274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.